Personalis (NASDAQ: PSNL)
Personalis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Personalis Company Info
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.
News & Analysis
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.
Why Personalis Stock Dropped Today
The company announced the pricing of a public offering of common stock.
If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now
Investors weren't very happy when shares tanked in March, but have been smiling ever since.
Personalis Turns to Liquid Biopsies for Growth. Will It Work?
The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.
Here's Why Personalis Fell as Much as 13.8% Today
The genomics company announced a public offering of common stock.
2 Top Small-Cap Stocks to Buy in December
These small-cap biopharma stocks offer intriguing potential in 2020 and beyond.
Here's Why Liquid Biopsy Stocks Fell as Much as 39.2% in September
Is Wall Street's initial excitement giving way to more realistic expectations?
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Earnings Transcripts
Personalis, Inc. (PSNL) Q1 2020 Earnings Call Transcript
PSNL earnings call for the period ending March 31, 2020.
Personalis, Inc. (PSNL) Q4 2019 Earnings Call Transcript
PSNL earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.